Sign in
Matthew Guggenbiller

Matthew Guggenbiller

Research Analyst at Bank of America Corp. /de/

New York, NY, US

Matthew Guggenbiller is an Equity Research Analyst at Bank of America, specializing in U.S. biopharmaceuticals with a particular focus on healthcare companies such as HUTCHMED China Limited and REGENXBIO. He regularly provides in-depth coverage and analysis for major public biopharma firms, actively participating in industry conferences and company earnings calls, though specific performance metrics or third-party rankings are not publicly documented. Guggenbiller's professional background centers on equity research, and he has been with Bank of America for several years, contributing to the institutional investment community. While publicly available sources do not specify securities licenses or FINRA registration, his analyst role at a major investment bank suggests adherence to industry regulatory standards.

Matthew Guggenbiller's questions to Intellia Therapeutics (NTLA) leadership

Question · Q2 2025

Representing Alex Stranahan of Bank of America, Matthew Guggenbiller asked if the changes to enrollment targets and stabilizer percentage in the MAGNITUDE study have altered the company's thinking on the likelihood or timing of a potential interim readout.

Answer

President and CEO John Leonard confirmed that the adjustments increase the overall statistical power of the study for both the primary outcome and the stabilizer subgroup. He stated an expectation that these changes would "favorably affect the ability to find an effect" at the point of a future interim analysis.

Ask follow-up questions

Fintool

Fintool can predict Intellia Therapeutics logo NTLA's earnings beat/miss a week before the call

Matthew Guggenbiller's questions to AGIOS PHARMACEUTICALS (AGIO) leadership

Question · Q2 2025

Matthew Guggenbiller of Bank of America inquired about the educational strategy to drive Pyrokine uptake beyond the initial target patients in thalassemia and asked if development plans for the PKU asset, AG-181, have changed following a competitor's recent approval.

Answer

CCO Tsveta Milanova detailed plans to expand to less acute non-transfusion-dependent patients by educating on long-term complications. CMO Dr. Sarah Gheuens stated there are no changes to the PKU program, emphasizing AG-181's novel mechanism and the remaining unmet need in the patient population.

Ask follow-up questions

Fintool

Fintool can predict AGIOS PHARMACEUTICALS logo AGIO's earnings beat/miss a week before the call

Let Fintool AI Agent track Matthew Guggenbiller for you

Get briefed when they ask questions on calls

Best AI Agent for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Try Fintool for free